| 000 | 01541 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250514001614.0 | ||
| 264 | 0 | _c20011204 | |
| 008 | 200112s 0 0 eng d | ||
| 022 | _a1234-1010 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZahorska-Markiewicz, B | |
| 245 | 0 | 0 |
_aNeuropeptide Y in obese women during treatment with adrenergic modulation drugs. _h[electronic resource] |
| 260 |
_bMedical science monitor : international medical journal of experimental and clinical research _c |
||
| 300 |
_a403-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenergic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAdrenergic alpha-Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Obesity Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 |
_aCaffeine _xtherapeutic use |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 |
_aCentral Nervous System Stimulants _xtherapeutic use |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 |
_aEphedrine _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeuropeptide Y _xblood |
| 650 | 0 | 4 |
_aObesity _xblood |
| 650 | 0 | 4 | _aRadioimmunoassay |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aYohimbine _xtherapeutic use |
| 700 | 1 | _aObuchowicz, E | |
| 700 | 1 | _aWaluga, M | |
| 700 | 1 | _aTkacz, E | |
| 700 | 1 | _aHerman, Z S | |
| 773 | 0 |
_tMedical science monitor : international medical journal of experimental and clinical research _gvol. 7 _gno. 3 _gp. 403-8 |
|
| 999 |
_c11316997 _d11316997 |
||